View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 27, 2022

Clarify Health unveils cloud software to improve clinical trial diversity

The analytics of the software is based on a dataset that comprises SDoH data at the patient level for a variety of aspects

Clarify Health has launched the real-world evidence-based cloud software, Clarify Trials, designed to aid life sciences companies to enhance the recruitment of clinical trial subjects from diverse and underrepresented communities.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The software offers more than 400 social determinants of health (SDoH) insights to help research sites as well as investigators to enrol patients from diverse populations into the trials.

It also helps in evaluating the referral patterns of doctors to facilitate coordinated outreach within underserved people. 

Furthermore, it allows life sciences companies and clinical research organisations to lower health inequalities without unwarranted delays in the trial, budget overruns, or change in protocol, while they navigate the 2020 guidance of the Food and Drug Administration to boost trial diversity.

The analytics of the software is based on a dataset that comprises SDoH data at the patient level for a variety of aspects, including race, gender, level of income, ethnicity, access to transportation, stability in housing, education level and health literacy.

More than 300 million patient lives are covered by these data, which are connected to government and commercial claims, prescription, clinical and dispensing information. 

Life sciences firms could assess disparities in health within different patient groups and enrol people who best represent the future patient population of their treatment.

Clarify Health CEO Jean Drouin said: “Greater clinical trial diversity has an important role to play in tackling undeniable disparities in healthcare. 

“Clarify’s patient journey analytics deliver socio-behavioural insights to ensure the people most in need are included in clinical research, accurately diagnosed and prescribed the right therapy.”

The cloud-based business applications of the company leverage the Clarify Atlas Platform that charts more than 300 million patient journeys to provide over 18 billion artificial intelligence-driven predictions and surface insights quickly and accurately. 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena